APLM Live signaler | Maksimer profitt med Getagraph.com

KJøP 145558 min ago

@ $0.675

Utstedt: 9 feb 2024 @ 15:59

Avkastning: -53.00%

Forrige signal: feb 7 - 15:54

Forrige signal: Selg

Avkastning: 4.44 %

Live Chart Being Loaded With Signals

Commentary (20 mai 2024 @ 18:40):

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia...

Stats
Dagens volum	171 658
Gjennomsnittsvolum	178 103
Markedsverdi	28.37M
EPS	$0 ( 2024-04-26 )
Neste inntjeningsdato	( $0 ) 2024-06-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0.00500 (1.58%)

Volum Korrelasjon

Lang: -0.18 (neutral)

Kort: -0.24 (neutral)

Signal:(47.701) Neutral

Apollomics, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Apollomics, Inc. Korrelasjon - Valuta/Råvare

0.06
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.65
( weak negative )

Apollomics, Inc. Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.77

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-2.77

Financial Reports:

No articles found.

Apollomics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Apollomics, Inc.

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.